CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal

By Akshay Kedari  Date: 2020-10-12

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted strategic collaboration with Pfizer which it had announced back in September 2020.

Reportedly, Hong Kong’s Listing Committee Of The Stock Exchange had given a green light for the listing of 115,928,803 additional shares bought at a price of HK$13.37 per share by Pfizer. With this purchase, Pfizer now owns almost a 9.90 percent stake in CStone Pharmaceuticals.

According to reliable sources, CStone’s Share Subscription Agreement comes as a part of the strategic collaboration framework with Pfizer to accelerate its commercial, financial and strategic objectives as it moves to become a fully integrated biopharma firm.

After the completion of this agreement, Pfizer will have an exclusive license to commercialize CStone’s sugemalimab, one of its core late-stage assets in China and an anti-PD-L1 monoclonal antibody. Additionally, Pfizer and CStone would also be able to collaborate on the commercialization and development of additional oncology assets within the Greater China region.

Both the companies will have the option to pursue a selected basis joint in-licensing deal for supplementary oncology assets in the local market. Sources close to the matter cite that Goldman Sachs will act as CStone’s financial advisor, helping it to handle all the necessary transactions. As for legal advisors, Cooley will be representing CStone, and Clifford Chance will be representing Pfizer.

Speaking on the development, Pierre Gaudreault, Acting President, Pfizer China biopharmaceuticals group, said that this partnership builds on its longstanding history with CStone where Pfizer helped the Chinese biotech to develop a potential best-in-class PD-L1 therapy, which Pfizer will commercialize after receiving the required approval.

Besides, this new deal also strengthens its collaboration with a promising pharmaceutical firm that has remarkable clinical development capabilities.

Source Credit: http://www.cstonepharma.com/en/html/news/2470.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Hyundai Motor, LG Energy Solution to launch battery plant in Indonesia

Hyundai Motor, LG Energy Solution to launch battery plant in Indonesia

By Akshay Kedari

This new battery production plant will be built in the Karwang Regency. It will reportedly have a yearly output of around 10 gigawatt-hours of batteries. South Korean multinational conglomerates Hyundai Motor Company and LG Energy Solution Ltd. ...

Amazon’s ‘Key for Business’ raises security concerns for U.S apartments

Amazon’s ‘Key for Business’ raises security concerns for U.S apartments

By Akshay Kedari

American technology and e-commerce giant, Amazon.com Inc. has reportedly been using ‘Key for Business’- a system that enables the company’s delivery agents to gain access to apartment complexes without requiring to be buzzed in by r...

Volvo Cars might take full control of its Chinese stake ahead of IPO

Volvo Cars might take full control of its Chinese stake ahead of IPO

By Akshay Kedari

Swedish luxury automobile manufacturer Volvo Cars Corporation reportedly signed an agreement with Zhejiang Geely Holding Group to buy out from their decade-long joint ventures to gain complete ownership of its facilities in China. According to relia...

Lamborghini expects sale volumes to hit record highs in India this year

Lamborghini expects sale volumes to hit record highs in India this year

By Akshay Kedari

Italian luxury sports car manufacturer, Automobili Lamborghini S.p.A. is reportedly expecting substantial growth in sales volumes in India this year as the carmaker is experiencing a V-shaped upturn in demand after the easing out of COVID-19 pandemic...

Netflix ventures into video games, hires former Oculus and EA developer

Netflix ventures into video games, hires former Oculus and EA developer

By Akshay Kedari

OTT streaming giant Netflix Inc. is reportedly planning to offer games on its platforms at no additional costs. The company has tapped Mike Verdu, a former Oculus and EA game development leader, to spearhead its games division. Verdu will join as th...